During the presentation portion of yesterdays’s earnings call, Niagen Bioscience CEO Rob Fried said the following:

”But it is critically important for everyone to understand that the NAD molecule itself is very large and is a nucleotide, meaning it cannot enter cells directly. It is therefore, ineffective at directly boosting NAD levels. 

One needs a precursor (NR, NMN) to enter the cell and then convert into NAD.

…This is likely the reason why NAD IVs take hours to ingest, and they have significant unpleasant side effects.

There are no studies that show that oral NAD supplementation increases cellular NAD.

Yet, as you know, we have over 40 published peer-reviewed clinical studies in NR”

Related:

FOLLOW us on Twitter @RaisingNAD